Reading additional input from stdin...
OpenAI Codex v0.144.6
--------
workdir: /home/administrator/Documents/promotion/claudius-proteomics
model: gpt-5.6-terra
provider: openai
approval: never
sandbox: read-only
reasoning effort: medium
reasoning summaries: none
session id: 01a033ef-fc73-78b1-8a7c-ba72480c6cfb
--------
user
You are an independent reviewer with deep proteomics + research-software-validation literacy. This is a POSTER PLAN (not code) for ECCB 2026 submission #1015, Posters track. Give a concrete, skeptical second opinion. Focus:

1) THESIS (§1): the plan claims LLM-assisted dev 'amplifies' validation gaps and explicitly disavows a causal 'relocation' claim (no control, no attribution). Is the amplification framing actually supported by the evidence presented, or is it still smuggling a causal claim? Is n=1 fatal for a posters track?

2) ABSTRACT (§A): honest, coherent, submittable? Does broadening from the titled 'proteomics infrastructure' to a 3-system portfolio (incl. structural biology / proteon) dilute focus or strengthen the team-scale claim? Is '~250k LOC' meaningful or vanity-metric?

3) EMPIRICAL CORE (§4.1) — the strongest panel: 'one mod_profile → two search engines (Sage 97.0%% vs FragPipe 77.3%% dataset-conformance) search different modification spaces; Sage PTM-aware, FragPipe PTM-blind.' Is this claim correctly scoped? Are the caveats (mass-only matching conflates isobaric sites; multi_ptm synthetic kit mis-scored) sufficient? Is calling it 'a real defect, not a design choice' overclaimed given you can't see runtime intent? What would a hostile MS-methods expert attack?

4) OVERLOAD: does adding proteon + cu-ims as 'breadth witnesses' strengthen or bury a single poster? 

5) FIGURES (§7, 5 panels): esp. fig 5 rendering the A2 finding as an EVIDENT typed-trust report (Verified/Judged/Absent). Does that land or feel circular/self-serving?

6) NOVELTY (§6) vs PROV / RO-Crate / MLflow / DVC — is the 'what plausibly remains' honest, or is typed-trust just repackaging?

Flag overclaims, missing controls, unstated assumptions, and anything that would embarrass the author before a validation-literate audience. Prioritize the 3-4 highest-value catches. Cap ~900 words.

<stdin>
# ECCB 2026 poster — LLM-assisted scientific infrastructure PLAN

**Status:** v3, 2026-08-24. Revises v2 (same day) after two changes: (a) the
author's decision to present the **full portfolio** (three operating systems +
EVIDENT), figure 5 anchored on the **A2 proteomics finding**, and the **abstract
treated as editable**; (b) a **first-hand read** of the `evident`, `proteon`,
and `cu-ims-primitives` repos (v2 described them second-hand) and the **full A2
sweep now run** (v2 had only a 3-dataset preview). For ECCB 2026 submission #1015
(Posters track, submitted 2026-04-20).

**What changed from v2:**

1. **Portfolio, not one system.** The "individual researcher builds team-scale
   infrastructure" claim is now evidenced by breadth: 3 operating systems across
   3 domains (§2, §3). proteon (structural biology) added.
2. **Figure 2 is the *full* A2 sweep, not a preview** — 128 datasets, real
   FragPipe-vs-Sage divergence numbers (§4.1).
3. **The intent question is settled.** The PTM is not globally missing — Sage
   has it, FragPipe does not; the two engines search different modification
   spaces from one profile (§4.1).
4. **Abstract rewritten** (§A) to name EVIDENT and the portfolio, since it is
   editable.
5. **Figure 5 renders the A2 finding as an EVIDENT TrustReport** — typed trust
   framing the poster's own evidence, not a bolt-on (§7).
6. Everything v2 removed/softened stays removed (§10 audit trail preserved).

---

## A. Revised abstract (editable — draft for submission)

**Title (recommended):** *LLM-Assisted Development of Large-Scale Proteomics
Infrastructure: Failure Modes and a Typed-Trust Remedy*
(keeps "proteomics" as the anchor; the portfolio generalises the pattern).

> In data-intensive fields such as proteomics and structural biology, the primary
> bottleneck is not only algorithm development but the construction and operation
> of scalable data infrastructure — work that typically requires large,
> specialized teams.
>
> We present an empirical study of infrastructure built by a single researcher
> using LLM-assisted development: a portfolio of three operating systems across
> three domains — a PRIDE timsTOF reanalysis pipeline (multi-engine search,
> raw-signal extraction, a versioned and bias-documented reference layer), a
> GPU-native diaPASEF primitive stack, and a Rust structural-bioinformatics
> toolkit — together ~250k lines of code. This is a rare setting to study
> infrastructure construction at scale and, critically, its validation.
>
> Analyzing the systems through version history and behavior under real data
> constraints, we identify failure modes that unit tests and successful-looking
> runs do not expose: configuration non-conformance (two search engines driven by
> one profile searching different modification spaces), silent nulls at
> external-service boundaries, and deployment–version-control divergence. These
> concentrate at configuration, deployment, and external-service boundaries, and
> are invisible to code review by humans *and* by models.
>
> We then present EVIDENT, a typed-trust framework separating Verified, Judged,
> and Absent evidence into a deterministic trust report, as a systematic
> validation strategy for LLM-assisted scientific software. These observations
> suggest such methods may let individual researchers build — and, crucially,
> *trust* — infrastructure that previously required dedicated teams.

Open: does ECCB permit editing the **title**, or only the body? If title is
locked, the body edit above still stands within the existing title.

---

## 0. Repos, paths, artifacts

| system | domain | local path | GitHub | state |
|---|---|---|---|---|
| **claudius-proteomics** | proteomics reanalysis (spine) | `~/Documents/promotion/claudius-proteomics` | `theGreatHerrLebert/claudius-proteomics` | `feat/hf-corpus`; poster docs + fig-2 committed |
| **proteon** | structural biology | `/scratch/TMAlign/proteon` | `theGreatHerrLebert/proteon` | `main` @ `c66b975`, v0.4.0, pip-published |
| **cu-ims-primitives** | GPU diaPASEF | `/scratch/ims/cu-ims-primitives` | `theGreatHerrLebert/cu-ims-primitives` | `feat/mbi-ms1-only` @ `9c86d15` |
| **evident** | validation meta / remedy | `/scratch/TMAlign/evident` | `theGreatHerrLebert/evident` | `docs/overview-examples` @ `93092b4` |

Key files for a reviewer:

- `evident/OVERVIEW.md`, `evident/concepts/typed-trust.md` — the typed-trust
  contract (Verified/Judged/Absent; deterministic synthesis).
- `evident/cases/cu-ims-primitives.md`, `evident/cases/proteon.md` — EVIDENT
  already carries both systems as cases; `concepts/typed-trust-proteon-fit.md` is
  the worked release-tier claim (CHARMM19+BALL electrostatics).
- `proteon/docs/ORACLE_SETUP.md`, `proteon/docs/validation.md`,
  `proteon/STABILITY.md` — validation-first structure, stable/experimental tiers.
- `cu-ims-primitives/README.md` — CPU/CUDA bit-parity + simulator ground truth.
- claudius: `runner/engines/fragpipe_job.py`, `scripts/run_fragpipe.py`,
  `runner/engines/sage_job.py`, `config/config.mogon.yaml` — the §4.1 path.
- `scripts/analysis/a2_conformance.py`, `A2_CONFORMANCE_RESULTS.md` — figure 2,
  committed (`065cc82`).
- Cluster (not reachable off-site): MOGON-NHR
  `/lustre/project/ki-proanagi/dateschn/data/processed/<ACC>/*/{fragpipe_output/fragpipe.workflow,sage/sage_config.json}`
  — the rendered-configuration artifacts that settle §4.1.

---

## 1. Thesis

> Fast, single-author, AI-assisted development amplifies verification and
> provenance gaps at **configuration, deployment, and external-service
> boundaries** — gaps that unit tests and successful-looking runs do not expose,
> and that are invisible to code review by humans *and* by models.

The final clause is earned by §4.4: during the review of this very plan, an
independent model reviewer read the relevant code, cited line numbers, and
reached a confident wrong conclusion — as had the plan's author. Only the run
artifacts settled it.

This is an **amplification** claim, not a causal *relocation* claim. There is no
non-LLM control, no time accounting, no commit-level attribution to model
assistance; a counterfactual is unsupported and not asserted (v1's error, kept
out).

---

## 2. What exists, quantitatively

Measured 2026-08-24 from the git repos. Report as **scale context**, not as
evidence for the thesis — file/line counts do not establish causality.

| | claudius | cu-ims | **proteon** | EVIDENT (remedy) |
|---|---|---|---|---|
| domain | proteomics | GPU diaPASEF | structural bio | validation meta |
| commits | 180 | 393 | **517** | 154 |
| code LOC | 42,292 | 40,649 | **167,340** | 42,187 |
| prose LOC (md) | 7,273 | 7,047 | **22,816** | 15,794 |
| test files | 15 | 29 | **140** | 90 |
| maturity | operational | behind SOTA (research) | v0.4 pip-published | early, tested |

**Three operating systems ≈ 250k lines of code across three domains, one
author.** Plus EVIDENT as the validation meta-framework. proteon is the most
mature (published package, stable/experimental API tiers, `CITATION.cff`).

Delivered output, to show this is operating infrastructure, not slideware:

- **claudius / HF corpus v0.2** — 58 datasets, 33,717,207 precursor rows,
  504,097,214 b/y fragment rows, 100% CC0.
- **proteon** — `pip install proteon`; batch structure I/O, SASA/DSSP/H-bonds,
  prep/minimization, TM-align, CHARMM19+BALL electrostatics, Vina docking.
- **cu-ims** — 17,814 peptides @1% FDR vs DiaNN 2.3's 50,482; reported as behind.
- **EVIDENT** — `typed-trust` engine + READ MCP server, `evident-agent` + EXEC
  MCP server, Claude/Codex driver. Deterministic orchestrator **sketched only**.

---

## 3. Spine and scope

**Spine: claudius-proteomics.** It matches the submitted abstract and holds the
measurable findings. **EVIDENT is the proposed remedy.** **proteon and cu-ims are
breadth witnesses** — evidence that the build-fast/validate-with-discipline
pattern generalises across domains — carried in the oracle figure (§7 fig 4), not
given co-equal narrative weight with the spine.

Discipline note: four systems on one poster is real claim-surface risk. The rule
is *claudius carries the argument; proteon + cu-ims carry the generalisation in a
single strip + one figure inset*. If space forces a cut, cu-ims goes first (it is
behind SOTA and its parity taxonomy is partly prospective), then proteon's
detail (keeping proteon only in the portfolio strip).

**O1 resolved:** abstract is editable → EVIDENT and the portfolio can be named
(§A). The poster is no longer constrained to proteomics-only framing.

---

## 4. The empirical core

### 4.1 Configuration non-conformance — the full A2 sweep (measured)

**This is the poster's strongest panel (figure 2), now the full sweep, not a
preview.** For every rendered engine config on the cluster, the *rendered* search
configuration is compared against the `mod_profile` that `config.mogon.yaml`
resolves for that accession. Reproducible: `scripts/analysis/a2_conformance.py`.

| engine | conforming datasets | where it breaks |
|---|---|---|
| **FragPipe** | **99/128 = 77.3%** | all non-conformance is PTM/HLA profiles; **0/90** generic-tryptic datasets fail |
| **Sage** | **128/132 = 97.0%** | tiny residual (2 phospho, 1 ubiq) |

**Two mechanisms, both measured:**

1. **The profile's PTM never renders into FragPipe** (25 datasets). Every PTM
   dataset's `msfragger.table.var-mods` enables only the LFQ-MBR default
   (Oxidation/M + N-term Acetyl); the target PTM is absent (Lactyl 72.021/K,
   Succinyl 100.016/K, GlyGly 114.043/K) or set `false` (Phospho 79.966/STY).
2. **4/12 HLA datasets render generic tryptic** (termini 2) instead of the
   profile's `nonspecific` (termini 0). **8/12 render correctly** — same
   pipeline, same class, two configurations. **Heterogeneity, not uniform
   breakage.**

**The intent question — settled.** The PTM is not globally missing: the Sage
config for the same datasets *does* carry it (verified in-file: PXD059168 Sage
`variable_mods {M:[15.99], K:[72.021129]}` = Lactyl-K searched, while its FragPipe
workflow enabled only Ox+N-term-Acetyl).

> **One `mod_profile` produced two engines searching different modification
> spaces** — Sage PTM-aware, FragPipe PTM-blind — for ~25 PTM datasets. Any
> cross-engine agreement step therefore compared a PTM-aware search against a
> PTM-blind one. A real defect in the FragPipe config path, not a design choice.

Caveats (on the board): mass-only PTM matching conflates isobaric sites (N-term
vs K Acetyl → PXD050342 false-conforms; true non-conformance is marginally
*higher*); PXD042416 (synthetic multi-PTM kit) is mis-scored on both engines by
the aggregate comparison — score subgroup-aware.

### 4.1b The silent no-op override (found while checking 4.1)

`scripts/run_fragpipe.py:132` rewrites lines matching
`msfragger.search_enzyme_name=`. FragPipe keys the enzyme as
`msfragger.search_enzyme_name_1=` (multi-enzyme format, FragPipe ≥20). The prefix
never matches, the loop replaces nothing, and **nothing checks the replacement
applied.** The `--enzyme` override is inert — the same failure class as the
PTM-render gap: an intended configuration silently not applied, in a system where
"the run succeeded" says nothing about whether the intended config was used.

### 4.1c A workflow name is not a stable configuration identifier

The *same* named base workflow ships different enzyme semantics across FragPipe
versions (23.1 `LFQ-MBR`: `stricttrypsin`, cleaves before P; 24 `LFQ-MBR`:
`trypsin`, does not). "We used LFQ-MBR" does not identify the search that ran.
**A5** — check whether `DATASET_CARD.md`/`SCHEMA.md` record a FragPipe version;
if not, that is a reproducibility gap in a shipped CC0 resource.

### 4.2 Deployment–VCS divergence (illustration, **not** a metric)

Retained as illustration of drift, with stated confounds (mtimes/`.bak-*` names
establish neither first execution nor which outputs used which version; n=4 is
not a distribution):

| change | live on cluster | committed | lag |
|---|---|---|---|
| `sage_overrides` | 2026-05-27 | 2026-08-24 | 89 d |
| `skip_msbooster` | 2026-06-01 | 2026-08-24 | 84 d |
| blob-resolver fix | 2026-07-23 | 2026-08-24 | 32 d |
| `fragpipe_workflow` pass-through | not deployed until 2026-08-24 | 2026-08-24 | — |

### 4.3 Silent nulls at external-service boundaries

PRIDE's **v2 `files/byProject` returns HTTP 200 with an empty body**. An audit
read that as "no raw files" and zeroed **191 of 544 datasets (35%)**. Caught only
by 20 controls where two sizing methods must agree; v3 + `fileCategory == RAW`
recovered 188 of 191 and 24.4 TB. **Admission for the poster:**
`scripts/audit_pool_size_license.py` — the tool written to *detect* this — has
the same defect (a `None` fetch failure is indistinguishable from an empty
listing). **A1: fix + commit the control table and archived responses.**

### 4.4 The review instance (meta — the reason for the thesis's last clause)

Reviewing this plan, an independent model read `fragpipe_job.py`,
`run_fragpipe.py`, `step2_search.py`, `config.mogon.yaml`, cited line numbers,
and concluded the enzyme override reached MSFragger. It does not (§4.1b). The
author had independently concluded the opposite error from an inaccurate code
comment still in the file. Neither careful human nor careful model reading
resolved it; the rendered artifact did, in one command. **The poster's argument
demonstrated on its own production**, at no extra cost — the evidence is in hand.

---

## 5. Two sound metrics (replacing "verification debt")

1. **Configuration conformance** — fraction of runs whose *rendered* engine
   configuration matches the resolved profile. §4.1 is the full sweep (both
   engines). This is figure 2 and the abstract's promised analysis.
2. **Execution provenance completeness** — fraction of runs carrying immutable
   code/config/input hashes. `scripts/cluster/_process_runner.sh` records a git
   SHA, a `working_tree_dirty` boolean, and a config SHA-256; the dirty flag
   proves ambiguity without identifying the diff, so affected runs are not
   reproducibly attributable from the recorded provenance alone.

**proteon is the positive control for both:** it *ships* validation-first —
`docs/ORACLE_SETUP.md`, stable/experimental API tiers, an `evident/` dir, and a
release-tier EVIDENT claim on its CHARMM19+BALL electrostatics. The contrast
(claudius: config drift found post-hoc; proteon: tolerances declared as typed
claims up front) is itself the poster's constructive half.

---

## 6. Novelty, positioned honestly

Prior art is real and must be cited, not implied absent: **W3C PROV**,
**RO-Crate / Workflow Run RO-Crate** (workflow-run provenance); **FAIR / FAIR4RS**
(research-software reuse); **MLflow / DVC** (parameter/artifact/lineage tracking).

What plausibly remains:

- A **concrete, executable case study** of configuration non-conformance in
  operating scientific infrastructure, with rendered-artifact evidence — not a
  provenance *model* or *standard*.
- **Typed trust**: Verified / Judged / Absent as distinct types with **Absent as
  a first-class result**, plus the binding rule that **synthesis is deterministic
  and calls no model**. A mechanism, not a checklist.
- **MCP as the neutral waist**: the same tools + prompt drive Claude or Codex —
  model-agnostic verification tooling.

**O6:** does typed trust survive contact with the differential-/metamorphic-
testing literature, or is it a repackaging? Lit check before printing.

---

## 7. Figures (five panels)

1. **The portfolio + the problem** — 3 systems × 3 domains × ~250k LOC, one
   author (the top strip); claudius at scale as the detailed case.
2. **Configuration conformance** ⭐ — the §4.1 full sweep: FragPipe 77.3% vs Sage
   97.0%, the two-engines-different-mods finding. The money figure *because it is
   measured*.
3. **The failure classes** — silent no-op override (§4.1b), silent API null
   (§4.3), deployment drift (§4.2, labelled illustration).
4. **The oracle question** — what do you check against with no ground truth?
   claudius (cross-engine agreement — correlated evidence, *not* an oracle),
   **cu-ims inset** (simulator truth + CPU/CUDA bit-parity), **proteon**
   (declared tolerances / oracle setup), **EVIDENT** (the manifest as oracle).
5. **Typed trust, worked** ⭐ — **the A2 finding rendered as an EVIDENT
   TrustReport**: *Verified* (the config artifact table), *Judged* (the
   Sage-vs-FragPipe mechanism), *Absent* (which invocation path selected
   `Nonspecific-HLA.workflow` for the 8 conforming HLA datasets — O5).

**Device:** tag every claim on the poster Verified / Judged / Absent. §4.1 is the
showcase — artifact table Verified, mechanism Judged, second invocation path
Absent until O5 closes.

---

## 8. Explicitly exploratory

- **n = 1, no control**; author = developer = analyst = subject.
- **No LLM attribution** in the commit record — "AI-assisted" is contextual.
- The A2 sweep is complete for claudius; the **portfolio-wide conformance metric
  is not run for proteon/cu-ims** (they use different engines/oracles).
- **EVIDENT's orchestrator is sketched, not built.**
- cu-ims is behind SOTA; its parity matrix is partly prospective.
- Generalisation beyond one developer / one toolchain is unestablished.

---

## 9. Hook

Lead with §4.1: *one config file, two search engines — Sage searched the
modification, FragPipe searched a generic default, and nothing noticed.* Then
§4.4: neither the author nor an independent model reviewer could settle it by
reading the code; the rendered artifact settled it immediately. Then hand the
audience typed trust as the proposed answer — and the portfolio as evidence one
person can build, and must be able to trust, infrastructure at this scale.

---

## 10. Claims removed or softened from v1/v2 (audit trail)

- "The bottleneck moves, and the new bottleneck has no established tooling" —
  removed; PROV/RO-Crate/MLflow/DVC contradict it.
- "The thesis is visible in the file counts" — removed; §2 is scale context only.
- "FragPipe silently fell back to its default tryptic workflow" / "every HLA
  dataset" / "wrong enzyme model for months" — **replaced with the measured full
  sweep** in §4.1 (heterogeneity; two-engine divergence).
- "the PTM was never searched" — **corrected**: Sage searched it, FragPipe did
  not (§4.1, the settled intent question).
- "cross-engine agreement as a mutual oracle" → "correlated evidence, not an
  oracle".
- "No equivalent published" — removed entirely.

---

## 11. Actions and open questions

- **A1** — fix the fetch-failure/empty-listing conflation in
  `scripts/audit_pool_size_license.py`; commit control table + archived
  responses (§4.3).
- **A2** — ✅ done: full configuration-conformance sweep, both engines
  (`A2_CONFORMANCE_RESULTS.md`, `scripts/analysis/a2_conformance.py`, committed).
- **A3** — fix the inaccurate comment in `runner/engines/fragpipe_job.py:90-95`
  (asserts the tryptic-fallback story §4.1 disproves).
- **A4** — fix/remove the inert `--enzyme` override in `run_fragpipe.py` (§4.1b),
  with a check that the replacement applied.
- **A5** — record FragPipe version in `DATASET_CARD.md`/`SCHEMA.md` (§4.1c).
- **A6** — render the A2 finding as an actual EVIDENT TrustReport (figure 5);
  confirm the manifest → TrustReport path produces it.
- **O1** — ✅ abstract editable; title-edit permission still unconfirmed (§A).
- **O5** — which invocation path selected `Nonspecific-HLA.workflow` for the two
  conforming datasets? (§4.1 Absent line).
- **O6** — does typed trust survive a differential/metamorphic-testing lit check?
- **O7** — publishing §4.1 admits a shipped corpus has non-conforming runs.
  Right call for credibility, or reprocess first and show the fix?
</stdin>
codex
I’ll review this as a claim-evidence audit, with particular attention to whether the poster’s language outruns its single-system evidence and to where an MS-methods reviewer can puncture the configuration result.
web search: 
web search: W3C PROV recommendation provenance model entities activities agents ...
codex
Overall: promising poster if reframed as a rigorous single-case validation study. Its best asset is the rendered-config audit; its biggest liability is repeatedly converting “observed in an LLM-assisted project” into an implied effect of LLM assistance.

1. Thesis: “amplifies” is still causal language

“Amplifies verification gaps” asserts a comparative effect: more, larger, or harder-to-detect gaps than under some non-LLM baseline. Saying you do not claim “relocation” does not solve that. With no control, no time/commit attribution, and author-as-subject, the evidence supports only:

> “In one LLM-assisted infrastructure project, rendered-artifact validation exposed configuration, deployment, and service-boundary failures not exposed by the checks used during development.”

That is interesting and defensible. “LLM-assisted” can be context, not an explanatory variable. Likewise, “invisible to code review by humans and models” is too broad from one author’s mistaken reading plus one model review. Say: “not resolved by the code reviews performed here.”

n=1 is not fatal for Posters, provided it is plainly a case study / incident analysis with a reproducible artifact-level audit. It is fatal only to claims about LLM effects, prevalence, concentration of failure modes, or generalization across developers/toolchains. The poster should lead with “case study,” not “empirical study” in the quasi-comparative sense.

2. The A2 panel needs tighter denominators and a less absolute conclusion

This is genuinely strong, but a hostile MS reviewer will immediately ask why the comparison is **FragPipe 99/128** versus **Sage 128/132**. Are these the same accession–run–configuration units? If not, 77.3% versus 97.0% is not a comparable engine performance contrast. Define the unit, explain four extra Sage configurations, and show a paired table for the datasets run through both engines.

“Different modification spaces” is directionally right, but “modification space” is broader than presence of a target variable-mod mass. Search space also depends on residue/terminus specificity, fixed modifications, max variable modifications per peptide, peptide length/mass windows, enzyme specificity, open-search settings, localization/scoring, and engine-specific interpretation. Scope it to:

> “For the tested profiles, FragPipe omitted the profile-specified target variable PTM while Sage included it.”

The observed Sage/FragPipe mismatch makes an undocumented intentional design choice unlikely, but it does not prove intent. “A real defect, not a design choice” is overclaimed unless there is an explicit, versioned contract saying every engine must implement the resolved profile equivalently. The stronger defensible claim is: “a conformance defect relative to the stated `mod_profile` contract.” If that contract did not pre-exist, make the poster say it was reconstructed post hoc.

The two stated caveats are not sufficient. Add: PTM mass/tolerance and site matching are engine-semantic, not merely string/table matching; synthetic multi-PTM data require profile-specific expected sets; and rendered config is not necessarily executed config without command line, container/tool version, and log evidence. The cluster artifacts being off-site is a reproducibility weakness: archive a minimal hashed extraction of the relevant rendered configs, parser output, and exact FragPipe/MSFragger/Sage versions with the poster supplement.

3. Abstract/portfolio: focus beats scale theater

The abstract is mostly candid, but “rare setting,” “team-scale,” and “previously required dedicated teams” are unsupported sociological claims. ~250k LOC is context at best, and potentially vanity: it is highly sensitive to language, generated/vendor code, tests, and counting tool. Report it only with a reproducible counting policy and preferably replace the headline claim with concrete operational outputs (58 datasets, 33.7m precursors, published package, etc.).

Three systems strengthen a modest claim that the author has built across domains. They do not strengthen the validation conclusion, because only claudius has the quantified audit. Keep proteon/cu-ims as a narrow portfolio strip, not evidence of generalization. In the abstract, naming structural biology risks diluting a proteomics-track submission. I would retain one brief phrase (“with two additional research-software projects as contextual portfolio”) or omit them from the abstract entirely.

4. EVIDENT/figure 5 currently risks circularity

A TrustReport that labels the poster’s own A2 evidence Verified/Judged/Absent is a useful transparency device, but not yet evidence that EVIDENT is a remedy. It can read as: “we discovered a defect manually, then rendered our discovery in our framework.”

To land, figure 5 needs one prospective or operational demonstration: an explicit conformance contract, an input manifest, deterministic check, failed gate, and the action it prevents. Otherwise call EVIDENT a proposed reporting/checking pattern, not “a systematic validation strategy” or remedy. “Absent” is good epistemic hygiene, but not novel by itself; it resembles uncertainty/status annotation layered over provenance and assurance arguments.

The novelty section is more honest than prior versions, but must cite differential and metamorphic testing explicitly. Those literatures already address oracle-poor scientific software; Workflow Run RO-Crate already represents workflow-run inputs, outputs, code, and execution provenance, while PROV explicitly supports provenance used to assess trust. [Workflow Run RO-Crate](https://pmc.ncbi.nlm.nih.gov/articles/PMC11386446/), [W3C PROV overview](https://www.w3.org/TR/prov-overview/). The plausible contribution is therefore not a new provenance model: it is a small, executable, domain-grounded **conformance gate plus explicit evidence-status rendering**. That is enough for a poster—if presented modestly.
tokens used
20,405
Overall: promising poster if reframed as a rigorous single-case validation study. Its best asset is the rendered-config audit; its biggest liability is repeatedly converting “observed in an LLM-assisted project” into an implied effect of LLM assistance.

1. Thesis: “amplifies” is still causal language

“Amplifies verification gaps” asserts a comparative effect: more, larger, or harder-to-detect gaps than under some non-LLM baseline. Saying you do not claim “relocation” does not solve that. With no control, no time/commit attribution, and author-as-subject, the evidence supports only:

> “In one LLM-assisted infrastructure project, rendered-artifact validation exposed configuration, deployment, and service-boundary failures not exposed by the checks used during development.”

That is interesting and defensible. “LLM-assisted” can be context, not an explanatory variable. Likewise, “invisible to code review by humans and models” is too broad from one author’s mistaken reading plus one model review. Say: “not resolved by the code reviews performed here.”

n=1 is not fatal for Posters, provided it is plainly a case study / incident analysis with a reproducible artifact-level audit. It is fatal only to claims about LLM effects, prevalence, concentration of failure modes, or generalization across developers/toolchains. The poster should lead with “case study,” not “empirical study” in the quasi-comparative sense.

2. The A2 panel needs tighter denominators and a less absolute conclusion

This is genuinely strong, but a hostile MS reviewer will immediately ask why the comparison is **FragPipe 99/128** versus **Sage 128/132**. Are these the same accession–run–configuration units? If not, 77.3% versus 97.0% is not a comparable engine performance contrast. Define the unit, explain four extra Sage configurations, and show a paired table for the datasets run through both engines.

“Different modification spaces” is directionally right, but “modification space” is broader than presence of a target variable-mod mass. Search space also depends on residue/terminus specificity, fixed modifications, max variable modifications per peptide, peptide length/mass windows, enzyme specificity, open-search settings, localization/scoring, and engine-specific interpretation. Scope it to:

> “For the tested profiles, FragPipe omitted the profile-specified target variable PTM while Sage included it.”

The observed Sage/FragPipe mismatch makes an undocumented intentional design choice unlikely, but it does not prove intent. “A real defect, not a design choice” is overclaimed unless there is an explicit, versioned contract saying every engine must implement the resolved profile equivalently. The stronger defensible claim is: “a conformance defect relative to the stated `mod_profile` contract.” If that contract did not pre-exist, make the poster say it was reconstructed post hoc.

The two stated caveats are not sufficient. Add: PTM mass/tolerance and site matching are engine-semantic, not merely string/table matching; synthetic multi-PTM data require profile-specific expected sets; and rendered config is not necessarily executed config without command line, container/tool version, and log evidence. The cluster artifacts being off-site is a reproducibility weakness: archive a minimal hashed extraction of the relevant rendered configs, parser output, and exact FragPipe/MSFragger/Sage versions with the poster supplement.

3. Abstract/portfolio: focus beats scale theater

The abstract is mostly candid, but “rare setting,” “team-scale,” and “previously required dedicated teams” are unsupported sociological claims. ~250k LOC is context at best, and potentially vanity: it is highly sensitive to language, generated/vendor code, tests, and counting tool. Report it only with a reproducible counting policy and preferably replace the headline claim with concrete operational outputs (58 datasets, 33.7m precursors, published package, etc.).

Three systems strengthen a modest claim that the author has built across domains. They do not strengthen the validation conclusion, because only claudius has the quantified audit. Keep proteon/cu-ims as a narrow portfolio strip, not evidence of generalization. In the abstract, naming structural biology risks diluting a proteomics-track submission. I would retain one brief phrase (“with two additional research-software projects as contextual portfolio”) or omit them from the abstract entirely.

4. EVIDENT/figure 5 currently risks circularity

A TrustReport that labels the poster’s own A2 evidence Verified/Judged/Absent is a useful transparency device, but not yet evidence that EVIDENT is a remedy. It can read as: “we discovered a defect manually, then rendered our discovery in our framework.”

To land, figure 5 needs one prospective or operational demonstration: an explicit conformance contract, an input manifest, deterministic check, failed gate, and the action it prevents. Otherwise call EVIDENT a proposed reporting/checking pattern, not “a systematic validation strategy” or remedy. “Absent” is good epistemic hygiene, but not novel by itself; it resembles uncertainty/status annotation layered over provenance and assurance arguments.

The novelty section is more honest than prior versions, but must cite differential and metamorphic testing explicitly. Those literatures already address oracle-poor scientific software; Workflow Run RO-Crate already represents workflow-run inputs, outputs, code, and execution provenance, while PROV explicitly supports provenance used to assess trust. [Workflow Run RO-Crate](https://pmc.ncbi.nlm.nih.gov/articles/PMC11386446/), [W3C PROV overview](https://www.w3.org/TR/prov-overview/). The plausible contribution is therefore not a new provenance model: it is a small, executable, domain-grounded **conformance gate plus explicit evidence-status rendering**. That is enough for a poster—if presented modestly.
